AnaptysBio Inc (NASDAQ: ANAB) made some noise on U.S. markets Tuesday after the company issued topline proof-of-concept data from Phase 2a trial of ANB020 In atropic dermatits.
The San Diego-based company announced early Tuesday that, After a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, the company says 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57.
All 12 patients achieved EASI-50 at one or more timepoints through Day 57 post-ANB020 administration. ANB020 was generally well tolerated in all patients as of this interim analysis.
Said CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.
“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”
The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.
AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.
Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
